Veterinary Pain Management Market To Reach $3.20 Billion By 2030

Veterinary Pain Management Market Growth & Trends

The global veterinary pain management market size is expected to reach USD 3.20 billion by 2030, registering a CAGR of 6.46% from 2024 to 2030, according to a new report by Grand View Research, Inc. The primary drivers of market growth include the advent of monoclonal antibodies in OA associated pain control, rising prevalence of diseases in animals such as osteoarthritis, rising pet ownership, increasing number of veterinarians, and increasing animal health expenditure.  In May 2023, Zoetis’s Librela mAb received the U.S. FDA approval for use in dog OA pain control. Moreover, pet insurance adoption is increasing due to a number of factors, including pet humanization, a growing pet population, greater initiatives by major companies, and rising veterinary care expenses.

Increasing number of veterinarians is expected to fuel the market growth. For instance, according to AVMA, there were a total of 127,131 vet practitioners in the U.S. veterinarians are now better equipped with tools and knowledge to identify and address pain in animals, whether it's acute or chronic. Moreover, there’s a greater emphasis on educating veterinarians about recognizing and managing pain in animals. Veterinary schools are incorporating pain management into their curricula, and continuing education programs keep practicing veterinarians up-to-date on the latest techniques and medications. Overall, the increasing number of veterinarians driving the veterinary pain management market reflects a positive shift towards better care and understanding of animals' needs, aligning with the broader trend of humanizing pets and recognizing their emotional and physical well-being.

Veterinary pain management has become a crucial aspect of pet care, particularly with conditions such as cancer, where pain can be a significant symptom. With the increase in cancer cases among dogs, there's likely a corresponding increase in the demand for effective pain management solutions in veterinary practice. Approximately fifty percent of dogs over the age of ten develop cancer. Cancer in dogs occurs at a rate similar to that of humans. There are certain cancers that affect cats more frequently than dogs, like lymphoma. In order to help manage pain in dogs with cancer, veterinarians frequently combine pharmaceuticals, such as analgesics and anti-inflammatory medicines, with complementary therapies, such as acupuncture and physical therapy.

Furthermore, ke, and acquisitions, regional expansions, etc., such as product launches, mergers and acquisitions, regional expansions, etc., to increase their foothold in the market. For instance, in January 2024, Ceva acquired Scout Bio, a leading biotechnology firm specializing in advanced therapies for pets. This acquisition marks a substantial advancement for Ceva, granting access to groundbreaking treatments such as monoclonal antibodies and gene therapy aimed to tackle chronic pet diseases.

 Request a free sample copy or view report summary: Veterinary Pain Management Market Report

Veterinary Pain Management Market Report Highlights

• Based on animal type, the production animals segment accounted for the largest market share in terms of revenue in 2023, owing to the rising prevalence of chronic illnesses, greater awareness among animal health organizations, and substantial costs associated with animal healthcare in emerging economies.

• Based on product, Nonsteroidal Anti-inflammatory Drugs (NSAIDs) segment accounted for the largest market share in terms of revenue in 2023.

• Based on indication, the osteoarthritis (OA) segment held largest market share in terms of revenue in 2023, owing to high prevalence of the disease; especially in canine animals.

• Based on end-use, hospitals & clinics segment dominated the veterinary pain management market with a share of over 82.71% in 2023.

• Based on mode of purchase, the prescription segment dominated the veterinary pain management market in 2023.

• Based on route of administration, the oral segment dominated the veterinary pain management market in 2023. Oral tablets are easier to administer compared to other forms of medication like injections.

• In 2023, North America accounted for the largest share of 38.26% in the veterinary pain management market.

Veterinary Pain Management Market Segmentation

Grand View Research has segmented the veterinary pain management market based on product, animal type, mode of purchase, indication, route of administration, end-use, and region:

Veterinary Pain Management Product Outlook (Revenue, USD Million, 2018 - 2030)

• NSAIDs

• Anesthetics

• Opioids

• Others

Veterinary Pain Management Animal Type Outlook (Revenue, USD Million, 2018 - 2030)

• Production Animals

• Companion Animals

Veterinary Pain Management Indication Outlook (Revenue, USD Million, 2018 - 2030)

• Osteoarthritis

• post-operative pain

• Others

Veterinary Pain Management Mode of Purchase Outlook (Revenue, USD Million, 2018 - 2030)

• Prescription

• OTC

Veterinary Pain Management Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

• Parenteral

• Oral

• Topical

Veterinary Pain Management End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals & Clinics

• Others

Veterinary Pain Management Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • India

  • China

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Veterinary Pain Management Market

• BOEHRINGER INGELHEIM

• VETOQUINOL

• CEVA ANIMAL HEALTH, LLC

• Chanelle Pharma (Exponent)

• ELANCO

• Dechra Pharmaceuticals Plc (EQT)

• ZOETIS

• MERCK & CO., Inc.

• Norbrook

• Assisi (Wind Point Partners)